Melanotan II: Everything You Need to Know

Melanotan II: A Research Overview

Melanotan II (MT-II) is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH) developed at the University of Arizona in the 1990s. Originally designed as a potential treatment for skin cancer by inducing protective tanning without UV exposure, MT-II gained widespread attention for its tanning effects and subsequently for its effects on sexual function and appetite.

Despite its popularity in certain communities, Melanotan II is not approved for medical use in any country and carries unique risks that set it apart from most other peptides. This guide provides a balanced, evidence-based overview.

How Melanotan II Works

MT-II is a non-selective agonist of melanocortin receptors, binding to MC1R through MC5R. Its wide-ranging effects are a direct consequence of this non-selectivity:

• MC1R activation: Stimulates melanocytes to produce melanin, resulting in skin darkening
• MC3R activation: Influences energy homeostasis and sexual function
• MC4R activation: Affects appetite suppression and sexual arousal
• MC5R activation: Involved in exocrine gland function

This non-selectivity is both the source of MT-II's multiple effects and the root of many of its side effects.

Research Findings

Tanning Effects

MT-II has been demonstrated to increase skin pigmentation independent of UV exposure in clinical studies. A study published in the Archives of Dermatology showed that MT-II produced significant darkening of the skin within days of administration. When combined with UV exposure, the tanning response is enhanced and prolonged compared to UV exposure alone.

Sexual Function

The sexual arousal effects of Melanotan II were an unexpected finding during initial research. Studies in both men and women have demonstrated increased sexual desire and arousal following MT-II administration. This led to the development of PT-141 (bremelanotide), a related peptide specifically targeting sexual dysfunction, which eventually received FDA approval.

Appetite Suppression

MT-II's activation of MC4R, a receptor centrally involved in appetite regulation, produces notable appetite suppression. Some users report significantly reduced food intake during MT-II use. This effect is being studied separately through more targeted melanocortin receptor agonists.

Side Effects and Safety Concerns

Melanotan II has a more concerning side effect profile than many other research peptides:

Common Side Effects

• Nausea: Very common, particularly in the early doses, sometimes severe
• Facial flushing: Occurs shortly after injection and typically lasts 30-60 minutes
• Fatigue and lethargy: Commonly reported following injections
• Spontaneous erections: A well-documented effect in males due to MC4R activation
• Darkening of moles and freckles: Existing pigmented lesions often darken more than surrounding skin
• Injection site reactions: Pain, redness, and swelling at injection sites

Serious Concerns

• Mole changes: MT-II can cause existing moles to darken, grow, and change in appearance. This complicates skin cancer screening, as changes in moles are a key warning sign for melanoma
• Melanoma risk: While MT-II was originally conceived to reduce melanoma risk through protective tanning, concerns have emerged about whether stimulating melanocyte activity could paradoxically promote melanoma in predisposed individuals. Case reports have documented melanoma in MT-II users, though causation has not been established
• Uneven pigmentation: Patchy or uneven skin darkening is common
• Cardiovascular effects: Elevated blood pressure has been reported

Melanotan II vs. Melanotan I (Afamelanotide)

Melanotan I, also known as afamelanotide and marketed as Scenesse, is a more selective MC1R agonist that has actually received regulatory approval in Europe for treating erythropoietic protoporphyria, a painful sun sensitivity condition. It produces tanning with fewer off-target effects than MT-II because of its greater receptor selectivity.

Key differences include:

• MT-I is more selective for MC1R, reducing sexual and appetite side effects
• MT-I has a shorter half-life than MT-II
• MT-I has been through formal clinical trials and regulatory approval (for a specific indication)
• MT-II produces faster and darker tanning but with more side effects

Regulatory and Legal Status

Melanotan II is not approved for human use in any country. Regulatory agencies including the FDA, TGA, and EMA have issued warnings against its use. It is widely available through online sources, but the quality and purity of these products are unregulated and unreliable.

Conclusion

Melanotan II is a powerful melanocortin receptor agonist with documented effects on skin pigmentation, sexual function, and appetite. However, its non-selectivity leads to a broad side effect profile, and the potential implications for mole changes and melanoma screening represent genuine concerns. Anyone considering MT-II should be aware of these risks, understand that it is an unapproved research compound, and consult with a dermatologist about skin monitoring protocols.